Total raised
$82.6M
Last: PIPE 2025-02
Stage
Public
Founded
2006
Headcount
26
HQ
Herzliya
Sector
Health Tech & Life Sciences
About
Firefly Neuroscience’s Brain Network Analytics (BNA™) technology provides an objective assessment of cognition (brain function). It records and compares how a brain functions to an FDA-cleared, normative, age-matched database using AI and advanced signal processing.
This allows clinicians and their patients to make informed, objective therapy and disease management decisions and track changes over time. Firefly Neuroscience takes the guesswork and subjectivity out of managing mental illnesses and cognitive disorders.
Funding history · 9 rounds · $82.6M total
2025-02
PIPE
$8.8M
2024-12
PIPE
$12.4M
2023-06
Undisclosed
$508K
2020-06
Series E
$3.5M
2019-04
Series D
$2.3M
2018-06
Series D
$6.4M
2015-11
Series C
$28.0M
2011-12
Series A
$13.8M
2006-06
Seed
$3.6M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Firefly Neuroscience become a public company and on which exchange?
- Firefly Neuroscience went public on NASDAQ in November 2021.
- What was Firefly Neuroscience's total funding raised as of the latest data?
- Firefly Neuroscience has raised a total of $82,588,527.
- What significant acquisition did Firefly Neuroscience complete in May 2025?
- In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc. for $6,000,000, which expanded its database, IP portfolio, and commercial footprint.
- Which organization did Firefly Neuroscience partner with in September 2025 to offer cognitive electrophysiology analytics?
- In September 2025, Firefly Neuroscience partnered with HealingMaps to offer its cognitive electrophysiology analytics to over 2,500 ketamine, psilocybin, and TMS clinics across North America.
- What was the purpose of Firefly Neuroscience's partnership with the Department of War in March 2026?
- In March 2026, Firefly Neuroscience confirmed a public-private partnership with the Department of War.
- What was the outcome of Firefly Neuroscience's collaboration with Bright Minds Biosciences in October 2024?
- In October 2024, Firefly Neuroscience collaborated with Bright Minds Biosciences to analyze data from its positive Phase 1 study using its AI, FDA-Cleared BNA™ Technology.
- What was the purpose of the joint venture RI.Mind formed by elminda (now Firefly Neuroscience) and RI.Group in March 2019?
- In March 2019, elminda and RI.Group formed RI.Mind, a joint venture to apply elminda's Brain Analytics Technology for the personalization of medical cannabis.
- What was the outcome of the merger agreement between WaveDancer and Firefly Neuroscience in March 2024?
- In March 2024, WaveDancer and Firefly Neuroscience each received respective stockholder approvals for their merger.
- What was the amount of the grant Firefly Neuroscience received from the IIA in March 2019?
- In March 2019, Firefly Neuroscience received a grant of $3,325,557 from the IIA.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
Artificial IntelligenceMachine LearningPlatforms & InterfacesSoftware
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProviders
Business model
B2B2C
Highlights
1 PatentsVerified
Tags
machine-learningpersonalizationbrain-disorderalzheimers-diseasedecision-supportmappingmental-healthpsychiatrydigital-healthcareneurologypharma-companiesmedical-devicesclinical-trialsimaginghealthcare-providersdegenerative-diseasesartificial-intelligencenon-invasivemedical-cannabisdiagnosticsparkinsonmedical-technologiesdeep-learningdoctorssaas